Thus, tocilizumab, an anti-IL6R [57], BHQ880, a monoclonal antibody against DKK1 [58], or tabalumab, a potent and selective fully human IgG4 MoAb with neutralizing activity against membrane-bound and soluble BAFF [59] are strategies that could be added to MM treatment. The gene discussed is TNFSF13B; the disease is Miyoshi myopathy.